Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 × 10&lt;SUP&gt;6&lt;/SUP&gt;/L CD4 Cell Counts&lt;SUBTITLE&gt;A Randomized Controlled Trial&lt;/SUBTITLE&gt;

Kahn, James O.; Cherng, Deborah Weng; Mayer, Kenneth H.; Murray, Henry; Lagakos, Stephen W.

doi:10.1001/jama.284.17.2193

Cited by 176 publications

(92 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A previous trial of this therapeutic vaccine, which examined chronic HIV-1 infected subjects with CD4 counts of 300-549 cells/ml on various antiviral therapies randomized to REMUNE or IFA, failed to demonstrate an effect of this therapeutic immunization on disease progression or death [16,17]. However, this trial predicted a 6% event rate, but, most likely due to the introduction of the protease inhibitors, a much lower event rate was observed (0·73%), potentially impacting on the conclusion of this trial.…”

Section: Discussionmentioning

confidence: 97%

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination

Moss

Wallace

Steigbigel

et al. 2002

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYWe treated a cohort of 38 HIV-infected individuals with a therapeutic vaccine (REMUNE, in an open label study. We then determined whether baseline parameters, such as CD4 cell count, viral load and IgG levels, were predictive of the magnitude of the HIV-specific lymphocyte proliferative responses (LPRs). We demonstrate herein that there is a significant enhancement from baseline for both HIV and p24 antigen-stimulated LPRs after immunization. Using a responder definition of a stimulation index of >5 on at least two post-immunization time-points, 29/38 (76%) responded to HIV-1 antigen while 27/38 (71%) responded to native p24 antigen. Viral load and total IgG were negatively correlated, while CD4 cell counts were positively associated with the magnitude of the HIV antigen LPR. In a multivariable analysis, baseline CD4 was the best predictor of HIV antigen LPR post-immunization.

show abstract

Section: Discussionmentioning

confidence: 97%

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination

Moss

Wallace

Steigbigel

et al. 2002

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…Therapeutic vaccination is one of the most promising strategies to restore HIV-specific T-cell responses in HIV infected patients and control viral replication without cART. 4 Initially, "classical approaches" such as whole inactivated virus (REMUNE) 5 or recombinant protein (gp120) 6 were tested as therapeutic vaccines. In general, the capacity of these early vaccines, as well as those based on DNA vectors 7 to increase the HIV-specific responses and control viral load were very limited.…”

Section: Introductionmentioning

confidence: 99%

Dendritic cell based vaccines for HIV infection

García

Plana

Climent

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Therapeutic vaccines of two phases 2 are now under experiments. In one trial, interim analysis of ad hoc, the immune function of HIV infected patient treated by ART had been improved [104][105][106][107][108]. As a result, this vaccine restores the immunity of infected peoples by the combination with ART.…”

Section: Developmental Study Of Hiv Vaccinementioning

confidence: 99%

Efficacy Trials and Progress of HIV Vaccines

Asif¹,

Irshad²

2017

J Cell Sci Ther

View full text Add to dashboard Cite

Discovery of HIV as causative agent of AIDS let to the belief that a vaccine for AIDS will be available shortly but was not that easy, and it took more than 30 years of hard laboratory and clinical work toward HIV vaccine development. Efficacy trials of RV144 and their results revealed that HIV vaccine is accomplishable. Clinical trials for developing bNAbs has monoclonal antibodies and to increase its half-life are also underway to achieve a proper HIV vaccine. In this review article, we see that how these efficacy trials are highlighting HIV vaccine concepts in clinical development. Therapeutic vaccines are proving to be a functional cure toward HIV treatment and progress is ongoing in such HIV vaccine development which will attack HIV before it fuses with cell and cause infection thus preventing AIDS. So, in near future it will be possible to cure HIV and bring an end to this epidemic.

show abstract

Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 × 10<SUP>6</SUP>/L CD4 Cell Counts<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Abstract: HIV-1 Immunogen with unrestricted ART failed to demonstrate an increase in HIV progression-free survival. JAMA. 2000;284:2193-2202.

Cited by 176 publications

References 32 publications

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination

Predictors of HIV-specific lymphocyte proliferative immune responses induced by therapeutic vaccination

Dendritic cell based vaccines for HIV infection

Efficacy Trials and Progress of HIV Vaccines

Contact Info

Product

Resources

About